Examining Differences in Opportunity and Eligibility for Cancer Clinical Trial Participation Based on Sociodemographic and Disease Characteristics
Overview
Affiliations
Purpose/objectives: To examine differences in opportunity and eligibility for cancer clinical trial (CCT) participation based on sociodemographic and disease characteristics. .
Design: A matched cross-sectional study including a prospective oral questionnaire and retrospective electronic medical record (EMR) review. .
Setting: A single hospital in a large academic National Cancer Institute-designated cancer center in Philadelphia, Pennsylvania. .
Sample: 44 Black or Hispanic and 44 Non-Hispanic White newly diagnosed individuals matched on cancer type and age (plus or minus five years). .
Methods: Participants answered a questionnaire to capture self-reported opportunity for CCT participation, sociodemographic information, and cancer type. With consent, the authors completed a retrospective review of the EMR to assess eligibility and collect cancer stage and performance status. .
Main Research Variables: Opportunity and eligibility for CCT participation. .
Findings: Most participants (78%) had no opportunity for participation and were ineligible for all available trials. No differences were noted in opportunity for participation or eligibility based on race or ethnicity. Participants with late-stage disease were more likely to have opportunity and be eligible for CCT participation (p = 0.001). Those with private insurance were less likely to have opportunity for participation (p = 0.05). .
Conclusions: Limited trial availability and ineligibility negatively influenced opportunity for CCT participation for all populations. Levels of under-representation for CCT participation likely vary within and across sociodemographic and disease characteristics, as well as across healthcare settings. .
Implications For Nursing: The unique roles of nurse navigators and advanced practice nurses can be leveraged to increase opportunities for CCT participation for all populations.
Riner A, Girma S, Vudatha V, Mukhopadhyay N, Skoro N, Gal T J Clin Oncol. 2022; 40(20):2193-2202.
PMID: 35316089 PMC: 9273372. DOI: 10.1200/JCO.21.02492.
Chen Y, Valent E, van Beers E, Kuiper R, Oliva S, Haferlach T Int J Lab Hematol. 2021; 44(1):127-134.
PMID: 34448362 PMC: 9290833. DOI: 10.1111/ijlh.13691.
Garrett S, Matthews T, Abramson C, Koenig C, Hlubocky F, Daugherty C JCO Oncol Pract. 2019; 16(1):e56-e63.
PMID: 31603726 PMC: 6993554. DOI: 10.1200/JOP.19.00256.
Barriers to non-small cell lung cancer trial eligibility.
Hardesty J, Kanarek N Contemp Clin Trials Commun. 2018; 9:45-49.
PMID: 29696224 PMC: 5898521. DOI: 10.1016/j.conctc.2017.11.010.
Shapiro E, Schamel J, Parker K, Randall L, Frew P Open Access J Clin Trials. 2017; 9:21-30.
PMID: 28804246 PMC: 5552064. DOI: 10.2147/OAJCT.S122422.